206 related articles for article (PubMed ID: 30771904)
1. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
[TBL] [Abstract][Full Text] [Related]
2. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
3. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
4. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
Buchan S; Manzo T; Flutter B; Rogel A; Edwards N; Zhang L; Sivakumaran S; Ghorashian S; Carpenter B; Bennett C; Freeman GJ; Sykes M; Croft M; Al-Shamkhani A; Chakraverty R
J Immunol; 2015 Jan; 194(1):125-133. PubMed ID: 25404365
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
6. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
7. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
8.
Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
[TBL] [Abstract][Full Text] [Related]
9. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
10. Ligation of CD27 on murine B cells responding to T-dependent and T-independent stimuli inhibits the generation of plasma cells.
Raman VS; Bal V; Rath S; George A
J Immunol; 2000 Dec; 165(12):6809-15. PubMed ID: 11120803
[TBL] [Abstract][Full Text] [Related]
11. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
[No Abstract] [Full Text] [Related]
12. GITR Agonism Enhances Cellular Metabolism to Support CD8
Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
[TBL] [Abstract][Full Text] [Related]
13. Quantitative contributions of TNF receptor superfamily members to CD8
Nguyen J; Pettmann J; Kruger P; Dushek O
Mol Syst Biol; 2021 Nov; 17(11):e10560. PubMed ID: 34806839
[TBL] [Abstract][Full Text] [Related]
14. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
15. Costimulation of T cells by OX40, 4-1BB, and CD27.
Croft M
Cytokine Growth Factor Rev; 2003; 14(3-4):265-73. PubMed ID: 12787564
[TBL] [Abstract][Full Text] [Related]
16. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily.
Nocentini G; Riccardi C
Eur J Immunol; 2005 Apr; 35(4):1016-22. PubMed ID: 15770698
[TBL] [Abstract][Full Text] [Related]
17. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
18. The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity.
He Y; Vlaming M; van Meerten T; Bremer E
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053463
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB costimulation promotes bystander activation of human CD8 T cells.
Reithofer M; Rosskopf S; Leitner J; Battin C; Bohle B; Steinberger P; Jahn-Schmid B
Eur J Immunol; 2021 Mar; 51(3):721-733. PubMed ID: 33180337
[TBL] [Abstract][Full Text] [Related]
20. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.
Ronchetti S; Zollo O; Bruscoli S; Agostini M; Bianchini R; Nocentini G; Ayroldi E; Riccardi C
Eur J Immunol; 2004 Mar; 34(3):613-622. PubMed ID: 14991590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
